Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 1(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05004285Phase 3Active Not Recruiting

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Role: lead

NCT05936658Phase 3Active Not Recruiting

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Role: lead

NCT05579184Phase 2Active Not Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2

Role: lead

NCT05458544Phase 1Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

Role: lead

NCT04528199Phase 1Terminated

[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Role: collaborator

NCT04509557Phase 1Completed

[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.

Role: lead

All 6 trials loaded